Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR-T cells are as effective as freshly infused cells

被引：0
|
作者：
Dreyzin, Alexandra [1 ]
Panch, Sandhya [2 ]
Shalabi, Haneen [3 ]
Yates, Bonnie [3 ]
Shah, Nirali [3 ]
Stroncek, David [2 ]
机构：
[1] Childrens Natl Hosp, Ctr Canc & Blood Disorders, Washington, DC USA
[2] NIH, Dept Transfus Med & Cellular Engn, Ctr Cellular Engn, Clin Ctr, Bldg 10, Bethesda, MD 20892 USA
[3] NCI, Pediat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
PEDIATRIC BLOOD & CANCER | 2022年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome
    Wickel, Jonathan
    Schnetzke, Ulf
    Sayer-Klink, Anne
    Rinke, Jenny
    Borie, Dominic
    Dudziak, Diana
    Hochhaus, Andreas
    Heger, Lukas
    Geis, Christian
    CELL REPORTS MEDICINE, 2024, 5 (11)
  • [22] IMPACT OF CRYOPRESERVATION ON BISPECIFIC ANTI-CD20/ANTI-CD19 CAR T-CELLS ENERGY METABOLISM AND ACTIVATION
    Poimenidou, M.
    McAllister, D.
    Nguyen, C. T.
    Johnson, B.
    Fenske, T.
    Hematti, P.
    Hamadani, M.
    Schenider, D.
    Kearl, T.
    Dwinell, M.
    Shah, N.
    CYTOTHERAPY, 2024, 26 (06) : S189 - S190
  • [23] Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins
    Herrera, L
    Yarbrough, S
    Ghetie, V
    Aquino, DB
    Vitetta, ES
    LEUKEMIA, 2003, 17 (02) : 334 - 338
  • [24] Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins
    L Herrera
    S Yarbrough
    V Ghetie
    D B Aquino
    E S Vitetta
    Leukemia, 2003, 17 : 334 - 338
  • [25] Deep Serological Profiling of Autoimmune Patients Treated with Anti-CD19 CAR-T Cells
    Nunez, Daniel
    Patel, Darshil
    Volkov, Jenell
    Wong, Steven
    Thompson, Dan
    Vorndran, Zachary
    Schett, Georg
    Basu, Samik
    MOLECULAR THERAPY, 2024, 32 (04) : 670 - 670
  • [26] Treatment of aggressive lymphomas with anti-CD19 CAR T cells
    Christopher A. Klebanoff
    Tori N. Yamamoto
    Nicholas P. Restifo
    Nature Reviews Clinical Oncology, 2014, 11 : 685 - 686
  • [27] Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity
    Rossi, Edmund A.
    Chang, Chien-Hsing
    Cardillo, Thomas M.
    Stein, Rhona
    Pilas, Diana
    Nordstrom, Diane L.
    Kopinski, John
    Goldenberg, David M.
    BLOOD, 2008, 112 (11) : 564 - 565
  • [28] THE ANTITUMOR-ACTIVITY OF AN ANTI-CD22 IMMUNOTOXIN IN SCID MICE WITH DISSEMINATED DAUDI LYMPHOMA IS ENHANCED BY EITHER AN ANTI-CD19 ANTIBODY OR AN ANTI-CD19 IMMUNOTOXIN
    GHETIE, MA
    TUCKER, K
    RICHARDSON, J
    UHR, JW
    VITETTA, ES
    BLOOD, 1992, 80 (09) : 2315 - 2320
  • [29] One CAR can hide another: anti-CD22 CAR-T cells in relapsed or refractory acute b-lymphoblastic leukemia
    Cailly, Laura
    Leleu, Xavier
    Moya, Niels
    HEMATOLOGIE, 2020, 26 (01): : 9 - 10
  • [30] Anti-CD19 CAR-T cell therapy for acquired hemophilia A
    Schultze-Florey, Christian R.
    Thol, Felicitas R.
    Aleksandrova, Krasimira
    Stoyanov, Kalin
    Gutierrez Jauregui, Rodrigo
    Arseniev, Lubomir
    Leise, Jana
    Kloess, Stephan
    Heidel, Florian H.
    Tiede, Andreas
    LEUKEMIA, 2025, : 980 - 982
12345